Open Access

High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group

  • Authors:
    • Iwona Hus
    • Joanna Mańko
    • Dariusz Jawniak
    • Artur Jurczyszyn
    • Grzegorz Charliński
    • Katarzyna Poniewierska‑Jasak
    • Lidia Usnarska‑Zubkiewicz
    • Mateusz Sawicki
    • Agnieszka Druzd‑Sitek
    • Alina Świderska
    • Anna Kopińska
    • Norbert Grząśko
    • Małgorzata Raźny
    • Aleksandra Wędłowska
    • Aleksander Perzyński
    • Aleksandra Gałązka
    • Dominik Dytfeld
    • Tadeusz Kubicki
    • Marek Rodzaj
    • Anna Waszczuk‑Gajda
    • Joanna Drozd‑Sokołowska
    • Bartłomiej Pogłódek
    • Anna Pasternak
    • Monika Długosz‑Danecka
    • Agnieszka Szymczyk
    • Anna Dmoszyńska
  • View Affiliations

  • Published online on: September 27, 2019     https://doi.org/10.3892/ol.2019.10929
  • Copyright: © Hus et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present retrospective analysis evaluated the efficacy and safety of the VTD (bortezomib, thalidomide, dexamethasone) regimen in 205 newly‑diagnosed patients with multiple myeloma (MM) eligible for high dose therapy and autologous stem cell transplantation (HDT/ASCT) in routine clinical practice. With a median of 6 cycles (range, 1‑8), at least partial response was achieved in 94.6% and at least very good partial response (VGPR) was achieved in 67.8% of patients. Peripheral neuropathy (PN) grade 2‑4 was observed in 28.7% of patients. In 72% of patients undergoing stem cell mobilization one apheresis allowed the number of stem cells sufficient for transplantation to be obtained. Following HDT/ASCT the sCR rate increased from 4.9 to 14.4% and CR from 27.8 to 35.6%. The results demonstrated that VTD as an induction regimen was highly efficient in transplant eligible patients with MM with increased at least VGPR rate following prolonged treatment (≥6 cycles). Therapy exhibited no negative impact on stem cell collection, neutrophils and platelets engraftment following ASCT. Therapy was generally well tolerated and PN was the most common reason of dose reduction or treatment discontinuation.

Related Articles

Journal Cover

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Hus, I., Mańko, J., Jawniak, D., Jurczyszyn, A., Charliński, G., Poniewierska‑Jasak, K. ... Dmoszyńska, A. (1899). High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group. Oncology Letters, 0, 0-0. https://doi.org/10.3892/ol.2019.10929
MLA
Hus, I., Mańko, J., Jawniak, D., Jurczyszyn, A., Charliński, G., Poniewierska‑Jasak, K., Usnarska‑Zubkiewicz, L., Sawicki, M., Druzd‑Sitek, A., Świderska, A., Kopińska, A., Grząśko, N., Raźny, M., Wędłowska, A., Perzyński, A., Gałązka, A., Dytfeld, D., Kubicki, T., Rodzaj, M., Waszczuk‑Gajda, A., Drozd‑Sokołowska, J., Pogłódek, B., Pasternak, A., Długosz‑Danecka, M., Szymczyk, A., Dmoszyńska, A."High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group". Oncology Letters 0.0 (1899): 0-0.
Chicago
Hus, I., Mańko, J., Jawniak, D., Jurczyszyn, A., Charliński, G., Poniewierska‑Jasak, K., Usnarska‑Zubkiewicz, L., Sawicki, M., Druzd‑Sitek, A., Świderska, A., Kopińska, A., Grząśko, N., Raźny, M., Wędłowska, A., Perzyński, A., Gałązka, A., Dytfeld, D., Kubicki, T., Rodzaj, M., Waszczuk‑Gajda, A., Drozd‑Sokołowska, J., Pogłódek, B., Pasternak, A., Długosz‑Danecka, M., Szymczyk, A., Dmoszyńska, A."High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group". Oncology Letters 0, no. 0 (1899): 0-0. https://doi.org/10.3892/ol.2019.10929